HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The impact of oral antiviral therapy on long-term survival of hepatitis B surface antigen-positive patients on haemodialysis.

AbstractAIMS:
Hepatitis B (HBV) is an important cause of morbidity and mortality in end-stage renal disease patients. The effect of oral antiviral therapy on survival in this population is not known. We evaluated the impact of oral antivirals on survival of HBV-infected haemodialysis patients.
METHOD:
This retrospective study included 52 HBsAg-positive haemodialysis patients and 156 non-infected haemodialysis controls. Criteria adopted for starting lamivudine were the 2001 American Association for the Study of Liver Diseases guidelines. Lamivudine was commenced in 21 (40.4%) patients, with median treatment duration of 58 months. The primary endpoint was transplant-free survival.
RESULTS:
Survival of HBsAg-positive patients was equivalent to that of age- and sex-matched HBsAg-negative controls (39.1% vs 33.2% at 10 years, respectively; P=0.12). In treated patients, complete viral suppression was associated with improved survival (serial HBV DNA less than and equal to 2 log10 IU/mL, 90.9% vs HBV DNA >2 log10 IU/mL on at least one occasion, 74.1% at 5 years; P=0.049). Out of 20 deaths, three were liver-related.
CONCLUSION:
Haemodialysis patients with chronic HBV, when given oral antiviral therapy if indicated, had equivalent long-term survival to that of non-infected controls. In those with active viral hepatitis, viral suppression was associated with reduced liver-related mortality.
AuthorsMaggie M G Ow, Janak R de Zoysa, Edward J Gane
JournalThe New Zealand medical journal (N Z Med J) Vol. 127 Issue 1396 Pg. 34-42 (Jun 20 2014) ISSN: 1175-8716 [Electronic] New Zealand
PMID24997462 (Publication Type: Journal Article)
Chemical References
  • Hepatitis B Surface Antigens
  • Reverse Transcriptase Inhibitors
  • Lamivudine
Topics
  • Administration, Oral
  • Aged
  • Female
  • Hepatitis B (complications, drug therapy)
  • Hepatitis B Surface Antigens (blood)
  • Humans
  • Kaplan-Meier Estimate
  • Kidney Failure, Chronic (complications, therapy)
  • Kidney Transplantation
  • Lamivudine (therapeutic use)
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Renal Dialysis
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors (therapeutic use)
  • Survivors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: